Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 101 to 150 of 600 results for women's health

  1. Maternity and mental health

    newborns Women can develop mental ill health for the first time during pregnancy, and pre-existing mental...

  2. Ovarian cancer: identifying and managing familial and genetic risk (NG241)

    This guideline covers assessing the familial and genetic risk of having a pathogenic variant associated with ovarian cancer in adults.

  3. Dementia, disability and frailty in later life – mid-life approaches to delay or prevent onset (NG16)

    This guideline covers mid-life approaches to delay or prevent the onset of dementia, disability and frailty in later life. The guideline aims to increase the amount of time that people can be independent, healthy and active in later life.

  4. Pregnancy and neonates: postnatal mental health (IND178)

    This indicator covers the percentage of women who have given birth in the preceding 12 months who have had an enquiry about their mental health between 4 to 16 weeks postpartum. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM156

  5. Healthy start vitamins: special report on cost effectiveness (ECD5)

    Healthy start vitamins: special report on cost effectiveness

  6. Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women (TA160)

    Evidence-based recommendations on raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women.

  7. Sapropterin for treating hyperphenylalaninaemia in phenylketonuria (TA729)

    Evidence-based recommendations on sapropterin for treating hyperphenylalaninaemia in phenylketonuria.

  8. Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (TA161)

    Evidence-based recommendations on raloxifene and teriparatide for preventing osteoporotic fragility fractures in postmenopausal women who have osteoporosis.

  9. Bipolar disorder: assessment and management (CG185)

    This guideline covers recognising, assessing and treating bipolar disorder (formerly known as manic depression) in children, young people and adults. The recommendations apply to bipolar I, bipolar II, mixed affective and rapid cycling disorders. It aims to improve access to treatment and quality of life in people with bipolar disorder.

  10. Pregnancy and neonates: mental health at booking appointment (IND63)

    This indicator covers proportion of pregnant women who were asked about their mental health at their first booking appointment. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG82

  11. Topotecan for the treatment of recurrent and stage IVB cervical cancer (TA183)

    Evidence-based recommendations on topotecan for treating recurrent and stage IVB cervical cancer in adults.

  12. Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes (TA572)

    Evidence-based recommendations on ertugliflozin (Steglatro) as monotherapy or with metformin for treating type 2 diabetes in adults.

  13. Rehabilitation for adults with complex psychosis (NG181)

    This guideline covers mental health rehabilitation for adults with complex psychosis. It aims to ensure people can have rehabilitation when they need it and promotes a positive approach to long-term recovery. It includes recommendations on organising rehabilitation services, assessment and care planning, delivering programmes and interventions, and meeting people’s physical healthcare needs.

  14. Behaviour change: general approaches (PH6)

    This guideline covers a set of principles that can be used to help people change their behaviour. The aim is for practitioners to use these principles to encourage people to adopt a healthier lifestyle by, for example, stopping smoking, adopting a healthy diet and being more physically active.

  15. Abaloparatide for treating osteoporosis in postmenopausal women [ID882]

    In development [GID-TA10071] Expected publication date: TBC

  16. Cancer: breast screening (50 to 70 years) (IND65)

    This indicator covers the proportion of women aged 50 to 70 years whose record shows a breast screening test has been performed within the last 3 years. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG84

  17. Everolimus with exemestane for treating advanced breast cancer after endocrine therapy (TA421)

    Evidence-based recommendations on everolimus (Afinitor) for treating advanced breast cancer in adults after endocrine therapy.

  18. Osteoporosis (QS149)

    This quality standard covers managing osteoporosis in adults (aged 18 and over), including assessing risk and preventing fragility fractures. It describes high-quality care in priority areas for improvement.

  19. Physical health of people in prison (NG57)

    This guideline covers assessing, diagnosing and managing physical health problems of people in prison. It aims to improve health and wellbeing in the prison population by promoting more coordinated care and more effective approaches to prescribing, dispensing and supervising medicines.

  20. HIV testing: increasing uptake among people who may have undiagnosed HIV (NG60)

    This guideline covers how to increase the uptake of HIV testing in primary and secondary care, specialist sexual health services and the community. It describes how to plan and deliver services that are tailored to the local prevalence of HIV, promote awareness of HIV testing and increase opportunities to offer testing to people who may have undiagnosed HIV.

  21. Domestic violence and abuse: multi-agency working (PH50)

    This guideline covers planning and delivering multi-agency services for domestic violence and abuse. It aims to help identify, prevent and reduce domestic violence and abuse among women and men in heterosexual or same-sex relationships, and among young people.

  22. Contraception: advice for people with bipolar, schizophrenia or other psychoses (IND124)

    This indicator covers the percentage of women with schizophrenia, bipolar affective disorder or other psychoses under the age of 45 years who have been given information and advice in the previous 12 months about pregnancy, conception or contraception tailored to their pregnancy and contraceptive intentions. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM78

  23. Spondyloarthritis (QS170)

    This quality standard covers diagnosing and managing spondyloarthritis in adults aged 16 and over. It describes high-quality care in priority areas for improvement.

  24. Commentary - maternity and neonatal care

    way that would have been unthinkable to our grandparents. This means that women and their partners have higher expectations about the...

  25. Ovarian cancer (advanced): bevacizumab 7.5 mg/kg in combination with paclitaxel and carboplatin for first-line treatment (ESUOM21)

    Summary of the evidence on bevacizumab 7.5 mg/kg with paclitaxel and carboplatin for the first-line treatment of advanced ovarian cancer..

  26. Skin cancer (QS130)

    This quality standard covers preventing, assessing, diagnosing and managing skin cancer (melanoma and non-melanoma skin cancer). It describes high-quality care in priority areas for improvement.

  27. Weight management: lifestyle services for overweight or obese adults (PH53)

    This guideline covers multi-component lifestyle weight management services including programmes, courses, clubs or groups provided by the public, private and voluntary sector. The aim is to help people lose weight and become more physically active to reduce the risk of diseases associated with obesity. This includes coronary heart disease, stroke, type 2 diabetes and various cancers.

  28. Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy (TA687)

    Evidence-based recommendations on ribociclib (Kisqali) for treating hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in adults who have had previous endocrine therapy.

  29. Surgical site infection (QS49)

    This quality standard covers preventing and treating surgical site infections. It covers adults, young people and children having a surgical procedure that involves a cut to the skin in all healthcare settings. It describes high-quality care in priority areas for improvement.

  30. Donor milk banks: service operation (CG93)

    This guideline covers how donor milk banks should recruit, screen and support women who donate breast milk. It also covers how milk banks should handle and process the breast milk they receive from donors. It aims to improve the safety of donor milk and operation of donor milk services.

  31. Mental health of adults in contact with the criminal justice system (NG66)

    This guideline covers assessing, diagnosing and managing mental health problems in adults (aged 18 and over) who are in contact with the criminal justice system. It aims to improve mental health and wellbeing in this population by establishing principles for assessment and management, and promoting more coordinated care planning and service organisation across the criminal justice system.

  32. Drug misuse in over 16s: opioid detoxification (CG52)

    This guideline covers helping adults and young people over 16 who are dependent on opioids to stop using drugs. It aims to reduce illicit drug use and improve people’s physical and mental health, relationships and employment.

  33. High-sensitivity troponin tests for the early rule out of NSTEMI (DG40)

    Evidence-based recommendations on high-sensitivity troponin tests for the early rule out of NSTEMI (non-ST-segment elevation myocardial infarction)

  34. Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer (TA389)

    Evidence-based recommendations on topotecan, pegylated liposomal doxorubicin hydrochloride (Caelyx; PLDH), paclitaxel, trabectedin (Yondelis) and gemcitabine. These drugs are for people with ovarian cancer that has come back some time after it was first treated.

  35. Skin cancer prevention (PH32)

    This guideline covers new buildings and communal outdoor areas. The aim is to ensure there are enough shady areas to protect people from overexposure to the sun.

  36. Type 2 diabetes: prevention in people at high risk (PH38)

    This guideline covers how to identify adults at high risk of type 2 diabetes. It aims to remind practitioners that age is no barrier to being at high risk of, or developing, the condition. It also aims to help them provide those at high risk with an effective and appropriate intensive lifestyle-change programme to prevent or delay the onset of type 2 diabetes. The recommendations in this guideline can be used alongside the NHS Health Check programme .

  37. MoreLife MUMS2B (expecting parents) and 4MUMS (new parents)

    obstetric populations share the aim of NICE guideline PH27: to help all women who have a baby to achieve and maintain a healthy weight...

  38. Familial hypercholesterolaemia (QS41)

    This quality standard covers identifying and managing familial hypercholesterolaemia (FH) in children, young people and adults. FH is a type of high cholesterol that runs in families and increases the risk of heart disease. The quality standard describes high-quality care in priority areas for improvement.

  39. Contraception: LARC for people on oral or patch contraceptives (IND148)

    This indicator covers the percentage of women, on the register, prescribed an oral or patch contraceptive method in the preceding 12 months who have also received information from the contractor about long acting reversible methods of contraception in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM114

  40. Pregnancy and neonates: smokers at delivery (IND19)

    This indicator covers the proportion of pregnant women who were smokers at the time of delivery. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG32

  41. COVID-19 rapid guideline: managing COVID-19 (NG191)

    This guideline covers managing COVID-19 in babies, children, young people and adults in community and hospital settings. It includes recommendations on communication, assessment, therapeutics for COVID-19, non-invasive respiratory support, preventing and managing acute complications, and identifying and managing co-infections.

  42. Length of postpartum stay and first midwife visit after transfer of care: How does the length of postpartum stay and the timing of the first midwife visit after transfer of care affect unplanned or emergency health contacts for women and babies?

    midwife visit after transfer of care affect unplanned or emergency health contacts for women and babies? Any explanatory...

  43. Abdominal aortic aneurysm: diagnosis and management (NG156)

    This guideline covers diagnosing and managing abdominal aortic aneurysms. It aims to improve care by helping people who are at risk to get tested, specifying how often to monitor asymptomatic aneurysms, and identifying when aneurysm repair is needed and which procedure will work best.

  44. Heavy menstrual bleeding (QS47)

    This quality standard covers assessing and managing heavy menstrual bleeding (menorrhagia), including suspected or confirmed fibroids and adenomyosis. It describes high-quality care in priority areas for improvement.

  45. Breast cancer (QS12)

    This quality standard covers the care of people with breast cancer after they have been referred to a specialist team. It includes the management of early (ductal carcinoma in situ and invasive), locally advanced and advanced breast cancer; recurrent breast cancer; and familial breast cancer. It describes high-quality care in priority areas for improvement.

  46. Colorectal cancer prevention: colonoscopic surveillance in adults with ulcerative colitis, Crohn's disease or adenomas (CG118)

    This guideline covers using colonoscopy to check for signs of bowel cancer in people aged 18 and over with ulcerative colitis or Crohn’s disease (types of inflammatory bowel disease) or adenomas (also known as polyps). It aims to prevent cancer and prolong life by offering advice on identifying early bowel cancer in adults most at risk.

  47. Neuropathic pain in adults: pharmacological management in non-specialist settings (CG173)

    This guideline covers managing neuropathic pain (nerve pain) with pharmacological treatments (drugs) in adults in non-specialist settings. It aims to improve quality of life for people with conditions such as neuralgia, shingles and diabetic neuropathy by reducing pain and promoting increased participation in all aspects of daily living. The guideline sets out how drug treatments for neuropathic pain differ from traditional pain management.

  48. Bisphosphonates for treating osteoporosis (TA464)

    Evidence-based recommendations on the bisphosphonates alendronic acid, ibandronic acid, risedronate sodium and zoledronic acid for treating osteoporosis.

  49. Leukomed Sorbact for preventing surgical site infection (MTG55)

    Evidence-based recommendations on Leukomed Sorbact for preventing surgical site infection after caesarean section or vascular surgery.

  50. Pregnancy and neonates: smokers at booking appointment (IND18)

    This indicator covers the proportion of pregnant women who were smokers at the time of their booking appointment. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG31